Skip to main content
PeptiDream Inc. logo

PeptiDream Inc. — Investor Relations & Filings

Ticker · 4587 ISIN · JP3836750004 T Manufacturing
Open in API
Filings indexed 71 across all filing types
Latest filing 2026-03-18 Audit Report / Informat…
Country JP Japan
Listing T 4587

About PeptiDream Inc.

https://www.peptidream.com/en/

PeptiDream Inc. is a biopharmaceutical company specializing in the discovery and development of novel therapeutics, primarily macrocyclic peptides. The company utilizes its proprietary Peptide Discovery Platform System (PDPS) to generate and screen extensive libraries of non-standard peptides, aiming to create a new class of innovative medicines. Its business model is centered on global collaborations and licensing agreements with pharmaceutical partners to advance drug discovery programs from hit identification to clinical candidates. PeptiDream's capabilities encompass various preclinical research disciplines, including discovery biology, medicinal chemistry, and pharmacology. Through a wholly-owned subsidiary, the company also markets and sells radiopharmaceutical and radiodiagnostic products.

Recent filings

Filing Released Lang Actions
確認書
Audit Report / Information Classification · 95% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act of Japan. This specific document is a mandatory attachment to an Annual Securities Report (Yukashoken Hokokusho) in Japan, where the CEO and CFO certify the accuracy of the report. Since it is a regulatory filing required by law to accompany the annual report but is not the annual report itself, and does not fit into other specific categories like 'RPA' or '10-K', it falls under the 'RNS' (Regulatory Filings) category as a miscellaneous regulatory disclosure. FY 2025
2026-03-18 Japanese
有価証券報告書－第20期(2025/01/01－2025/12/31)
Annual Report Classification · 100% confidence The document is a Japanese '有価証券報告書' (Yuuka Shouken Houkokusho), which is the standard Japanese equivalent of an Annual Report (10-K). It contains comprehensive financial data, management discussion, and business performance metrics for the fiscal year ending December 31, 2025. It is not an announcement or a summary, but the full statutory filing. FY 2025
2026-03-18 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act, signed by the CEO and CFO of PeptiDream Inc. It serves as an officer certification attesting to the accuracy of the company's interim report for the period ending June 30, 2025. According to the 'Certification Rule', documents that are primarily officer certifications or attestations, even if they reference a specific report type, should be classified as Regulatory Filings (RNS). H1 2025
2025-08-07 Japanese
半期報告書－第20期(2025/01/01－2025/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed with the Kanto Local Finance Bureau in Japan. It contains detailed financial statements, management analysis (MDA), and business descriptions for the period from January 1, 2025, to June 30, 2025. This document is a formal regulatory filing required under the Financial Instruments and Exchange Act of Japan, which corresponds to the 'Interim / Quarterly Report' (IR) category in the provided schema. H1 2025
2025-08-07 Japanese
内部統制報告書－第19期(2024/01/01－2024/12/31)
Governance Information Classification · 100% confidence The document header explicitly states the filing type as "【提出書類】 内部統制報告書" (Filing Document: Internal Control Report) and cites the legal basis as "金融商品取引法第24条の４の４第１項" (Financial Instruments and Exchange Act Article 24-4-4, Paragraph 1). This directly corresponds to the requirement for reporting on the effectiveness of internal controls over financial reporting, which is typically filed annually alongside the 10-K, but is a distinct report in Japanese regulatory filings. Given the specific nature of an 'Internal Control Report' (内部統制報告書) which details the framework, scope, and results of the internal control assessment, it aligns most closely with the 'Audit Report / Information' (AR) category, as it is a formal assessment of financial reporting integrity, although it is distinct from a pure external audit opinion. However, since the provided definitions do not have a specific code for 'Internal Control Report' (which is often filed as part of the 10-K structure in the US, but here is a standalone document type based on the header), I must choose the closest fit. The content is a formal assessment of financial reporting controls, making AR the most appropriate choice among the given options, as it deals with applied accounting principles and regulatory stress tests/assessments, which this report fundamentally is. The document is comprehensive, not just an announcement, ruling out RPA/RNS.
2025-03-28 Japanese
有価証券報告書－第19期(2024/01/01－2024/12/31)
Annual Report Classification · 100% confidence The document is a Japanese '有価証券報告書' (Yuuka Shouken Houkokusho), which is the standard Japanese equivalent of an Annual Report (10-K). It includes a header specifying the fiscal year (2024-01-01 to 2024-12-31), the company name (PeptiDream Inc.), and detailed financial tables (consolidated financial indicators). It is a comprehensive annual filing submitted to the Kanto Local Finance Bureau, not an announcement or a summary. FY 2024
2025-03-28 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.